Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, Regeneron, Roche ophthalmic news

Roche's Genentech unit amended a 2011 deal with Regeneron related to U.S. ophthalmic sales of Eylea aflibercept, a VEGF inhibitor, to settle patent litigation filed by Regeneron in 2011 in the

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE